youtube_live
Utili Q3 2026 • pubblicata • Utili per azione superati +8,62% • Fatturato superato +2,31%
Esamina i risultatichevron_right
EW:NYSE
Edwards Lifesciences
99,37Â USD
arrow_upward
+4,38%(+4,17) 1G
103,00Â USD
arrow_upward
+3,65% (+3,63)todayPre-market
Chiusura: 4 nov, 16:00:04 GMT-5 · USD
search
Tutti i simboli
| Simbolo | Prezzo | Cambio | % di cambio |
|---|
insights_autoGenerazione degli insight principali per EW in corso…
Apertura
98,58Â USD
Massimo
100,25Â USD
Minimo
96,72Â USD
Cap. mercato
57,28Â Mld
Vol. medio
4,00Â Mln
Volume
7,44K
Rapporto P/E
57,49
Max 52 sett.
100,25Â USD
Min 52 sett.
74,66Â USD
Utili per azione
1,73Â USD
Beta
0,85
Azioni in circolazione
576,40Â Mln
N. di dipendenti
16K
Apertura
98,58Â USD
Massimo
100,25Â USD
Minimo
96,72Â USD
Cap. mercato
57,28Â Mld
Vol. medio
4,00Â Mln
Volume
7,44K
Rapporto P/E
57,49
Max 52 sett.
100,25Â USD
Min 52 sett.
74,66Â USD
Utili per azione
1,73Â USD
Beta
0,85
Azioni in circolazione
576,40Â Mln
N. di dipendenti
16K
Articoli giornalistici
Da fonti web e partner giornalistici
Investing.com
·
1 ora fa
Wells Fargo raises Edwards Lifesciences price target on Q3 beat
BigGo Finance
·
11 ore fa
[Edwards Lifesciences Q3 2026 Earnings Call] Edwards Raises Full-Year Guidance to 11.5% Sales Growth and $3.01 EPS Midpoint After Q3 Beat; TAVR Growth to Rely on Market Expansion, Not Share Gains
TradingView
·
12 ore fa
Edwards Lifesciences Corporation reports results for the quarter ended September 30 - Earnings Summary
GuruFocus
·
12 ore fa
Edwards Lifesciences (EW) Q3 Earnings Beat Expectations, Raises Guidance
Profilo
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027. Wikipedia
Informazioni su Edwards Lifesciences
CEO-
Dipendenti16K
Data di fondazione1958
SedeIrvine, California, Stati Uniti
Settore-
Industry-
Sito webedwards.com